Seeking Alpha

Teva upbeat on NTE business prospects: Bloomberg

  • Teva (TEVA -0.4%) is betting its new therapeutic entities business (comprising "reformulated or repurposed" existing drugs) will generate as much as $3B in sales by 2020, Bloomberg reports.
  • The company is hoping the NTE business will go some ways towards offsetting lost revenue once Copaxone loses exclusivity.
  • While TEVA says it "believes that the NTE process will be an important growth driver," Bloomberg says some analysts (like Bernstein's Ronny Gal) aren't so sure.
  • Based on the pipeline, NTEs will include new abuse-deterrent opioids and treatments for schizophrenia and Parkinson’s.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)